Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.7.4127

MicroRNA-16 Inhibits Bladder Cancer Proliferation by Targeting Cyclin D1  

Jiang, Qi-Quan (Department of Urology, Affiliated Tongji Hospital, Tongji University)
Liu, Bin (Shanghai Institute of Materia Medica, Chinese Academy of Sciences)
Yuan, Tao (Department of Urology, Affiliated Tongji Hospital, Tongji University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.7, 2013 , pp. 4127-4130 More about this Journal
Abstract
MicroRNA-16 (miR-16) has been demonstrated to regulate proliferation and apoptosis in many types of cancers, but its biological function in bladder cancer remains unknown. Here, we found expression of miR-16 to be downregulated in bladder cancer in comparison with the adjacent normal tissues. Enforced expression of miR-16 was able to inhibit cell proliferation in TCHu-1 cells, in line with results for miR-16 antisense oligonucleotides (antisense miR-16). At the molecular level, our results further revealed that cyclin D1 expression was negatively regulated by miR-16. Therefore, the data reported here demonstrate that miR-16 is an important regulator in bladder cancer, which will contribute to better understanding of important mis-regulated miRNAs.
Keywords
MicroRNA-16; Cyclin D1; bladdercancer; cell proliferation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Berezikov E (2011). Evolution of microRNA diversity and regulation in animals. Nat Rev Genet, 12, 846-60.   DOI   ScienceOn
2 Dip N, Reis ST, Timoszczuk LS, et al (2012). Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol, 188, 1951-6.   DOI   ScienceOn
3 Esteller M (2011). Non-coding RNAs in human disease. Nat Rev Genet, 12, 861-74.   DOI   ScienceOn
4 Hanlon K, Rudin CE, Harries LW (2009). Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One, 4, e7169.   DOI   ScienceOn
5 Hu Z, Lin Y, Chen H, et al (2013). MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun, 435, 82-7.   DOI   ScienceOn
6 Jacobs BL, Lee CT, Montie JE (2010). Bladder cancer in 2010: how far have we come? CA Cancer J Clin, 60, 244-72.   DOI
7 Linsley PS, Schelter J, Burchard J, et al (2007). Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol, 27, 2240-52.   DOI   ScienceOn
8 Ma Q, Wang X, Li Z, et al (2013). microRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pathway. Oncol Rep, 29, 1652-8.
9 Majid S, Dar AA, Saini S, et al (2012). MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One, 7, e46743.   DOI
10 Malmstrom PU, Loskog AS, Lindqvist CA, et al (2010). AdCD40L immunogene therapy for bladder carcinoma the first phase I/IIa trial. Clin Cancer Res, 16, 3279-87.   DOI
11 Neely LA, Rieger-Christ KM, Neto BS, et al (2010). A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol, 28, 39-48.   DOI
12 Noguchi S, Yasui Y, Iwasaki J, et al (2013) Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett, 328, 353-61.   DOI   ScienceOn
13 O'Kelly F, Marignol L, Meunier A, et al (2012). MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol, 9, 397-407.   DOI   ScienceOn
14 Shimizu T, Suzuki H, Nojima M, et al (2013). Methylation of a Panel of MicroRNA Genes Is a Novel Biomarker for Detection of Bladder Cancer. Eur Urol, 63, 1091-100.   DOI   ScienceOn
15 Song T, Zhang X, Zhang L, et al (2013). miR-708 promotes the development of bladder carcinoma via direct repression of Caspase-2. J Cancer Res Clin Oncol, 139, 1189-98.   DOI   ScienceOn
16 Sun CY, She XM, Qin Y, et al (2013). miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis, 34, 426-35.   DOI   ScienceOn
17 Takeshita F, Patrawala L, Osaki M, et al (2010). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther, 18, 181-7.   DOI
18 van Kouwenhove M, Kedde M, Agami R (2011). MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer, 11, 644-56.   DOI   ScienceOn
19 Voutsinas GE, Stravopodis DJ (2009). Molecular targeting and gene delivery in bladder cancer therapy. J Buon, 14, S69-78.
20 Vardouli L, Lindqvist C, Vlahou K, et al (2009). Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther, 16, 848-60.   DOI   ScienceOn
21 Wang S, Xue S, Dai Y, et al (2012). Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol, 7, 159.   DOI
22 Zhang X, Wan G, Mlotshwa S, et al (2010). Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res, 70, 7176-86.   DOI
23 Zhu DX, Miao KR, Fang C, et al (2011). Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leuk Res, 35, 730-4.   DOI   ScienceOn
24 Pasquinelli AE (2012). MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet, 13, 271-82.